HC Wainwright Estimates Cytokinetics FY2026 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for Cytokinetics in a note issued to investors on Tuesday, January 20th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($5.70) for the year. HC Wainwright currently has a “Buy” rating and a $136.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ FY2027 earnings at ($3.45) EPS and FY2028 earnings at ($0.69) EPS.

Several other equities research analysts have also recently commented on CYTK. UBS Group reaffirmed a “neutral” rating and issued a $61.00 price objective on shares of Cytokinetics in a research report on Monday, December 1st. Barclays lifted their price target on Cytokinetics from $82.00 to $87.00 and gave the company an “overweight” rating in a research note on Monday, December 22nd. Wall Street Zen lowered Cytokinetics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Bank of America upped their price objective on Cytokinetics from $52.00 to $56.00 and gave the stock a “neutral” rating in a research report on Thursday, October 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $90.00 target price on shares of Cytokinetics in a research report on Friday, January 9th. Sixteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.00.

Cytokinetics Stock Down 1.2%

Cytokinetics stock opened at $63.04 on Wednesday. The company has a 50 day moving average of $64.00 and a 200-day moving average of $53.37. Cytokinetics has a twelve month low of $29.31 and a twelve month high of $70.98. The stock has a market capitalization of $7.71 billion, a PE ratio of -10.02 and a beta of 0.55.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.05. The business had revenue of $1.94 million for the quarter, compared to the consensus estimate of $6.05 million. Cytokinetics’s revenue for the quarter was up 318.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.36) earnings per share.

Insiders Place Their Bets

In related news, Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $64.73, for a total transaction of $323,650.00. Following the completion of the sale, the director owned 22,933 shares of the company’s stock, valued at $1,484,453.09. This represents a 17.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the completion of the transaction, the director directly owned 32,444 shares in the company, valued at approximately $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 159,544 shares of company stock valued at $10,347,509 over the last 90 days. 2.70% of the stock is owned by company insiders.

Institutional Trading of Cytokinetics

Several institutional investors have recently modified their holdings of the business. Quarry LP bought a new position in shares of Cytokinetics in the 3rd quarter worth about $30,000. Advisory Services Network LLC bought a new stake in Cytokinetics in the third quarter worth approximately $32,000. Johnson Financial Group Inc. bought a new position in shares of Cytokinetics during the 3rd quarter worth approximately $40,000. EverSource Wealth Advisors LLC increased its stake in shares of Cytokinetics by 723.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 673 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Cytokinetics during the 3rd quarter valued at $45,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.